menu search

CTXR / Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as earlier indicated. Read More
Posted: Jul 5 2022, 18:40
Author Name: Seeking Alpha
Views: 102548

CTXR News  

Citius Pharmaceuticals: Steer Clear From This One

By Seeking Alpha
June 2, 2023

Citius Pharmaceuticals: Steer Clear From This One

The article provides an updated analysis of Citius Pharmaceuticals following a previous piece in February 2023. Citius' lead therapy has a midsummer 2 more_horizontal

Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023

By PRNewsWire
January 11, 2023

Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023

CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical more_horizontal

Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days

By Seeking Alpha
November 8, 2022

Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days

Citius Pharmaceuticals, Inc. has a handful of catalysts set to occur in the next few months. Of these, some are critical to extending its cash runway more_horizontal

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

By Seeking Alpha
July 5, 2022

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee more_horizontal

Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022

By PRNewsWire
April 14, 2022

Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022

CRANFORD, N.J. , April 14, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutica more_horizontal

Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study

By Zacks Investment Research
April 7, 2022

Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study

Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lym more_horizontal

Shares of Citius jump 18% on new data for experimental lymphoma drug

By Market Watch
April 6, 2022

Shares of Citius jump 18% on new data for experimental lymphoma drug

Shares of Citius Pharmaceuticals Inc. CTXR, -1.60% were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from more_horizontal

Citius: 2022 Is A Year Of Catalysts

By Seeking Alpha
March 28, 2022

Citius: 2022 Is A Year Of Catalysts

5 Active Programs With Near Term Catalysts. more_horizontal


Search within

Pages Search Results: